#1 Clinical Trials Search in Europe

Tipranavir

Tipranavir is an antiretroviral medication used in the treatment of HIV infections. This article explores various clinical trials investigating the use of Tipranavir, often in combination with Ritonavir, for HIV patients. These studies focus on aspects such as bioequivalence, pharmacokinetics, safety, tolerability, and efficacy in different patient populations, including those with limited treatment options due to drug resistance or intolerance to other antiretroviral therapies.

Table of Contents

What is Tipranavir?

Tipranavir is an antiretroviral medication used in the treatment of HIV-1 infections. It’s also known by its brand name Aptivus[1]. Tipranavir belongs to a class of drugs called protease inhibitors, which work by preventing the HIV virus from multiplying in your body[2].

How Tipranavir Works

Tipranavir is always used in combination with another drug called ritonavir. This combination is often referred to as TPV/r. Ritonavir helps boost the effectiveness of tipranavir in your body[2]. Together, these drugs work to reduce the amount of HIV in your blood (known as viral load) and increase your CD4 cell count. CD4 cells are a type of white blood cell that helps your body fight infections[1].

Conditions Treated with Tipranavir

Tipranavir is specifically used to treat HIV-1 infections in patients who have:

  • Advanced HIV-1 disease
  • Failed other HIV treatments
  • Developed resistance to other protease inhibitors
It’s particularly useful for patients who have limited treatment options due to resistance to other HIV medications[3].

How Tipranavir is Administered

Tipranavir is available in two forms:

  • Soft elastic capsules containing 250 mg of tipranavir[4]
  • Oral solution (liquid form)[5]
It’s typically taken twice daily with food, always in combination with ritonavir. The usual adult dose is 500 mg of tipranavir with 200 mg of ritonavir[6].

Efficacy of Tipranavir

Clinical trials have shown that tipranavir, when used as part of a combination antiretroviral therapy, can effectively:

  • Reduce viral load (the amount of HIV in your blood)
  • Increase CD4 cell count (a type of white blood cell that fights infections)
In some studies, patients achieved a viral load of less than 50 copies/mL (which is considered undetectable) and a significant increase in CD4 count after 6 months of treatment[7].

Safety and Side Effects

Like all medications, tipranavir can cause side effects. Common side effects may include:

  • Changes in liver function
  • Alterations in blood cell counts
  • Changes in cholesterol and triglyceride levels
  • Gastrointestinal issues
Your healthcare provider will monitor these potential side effects through regular blood tests[2][1].

Long-term Use of Tipranavir

Several studies have looked at the long-term use of tipranavir. These studies aim to:

  • Assess the safety and tolerability of tipranavir over extended periods
  • Evaluate its long-term effectiveness in suppressing HIV
  • Identify any unexpected or late-occurring side effects
These studies help ensure that tipranavir remains safe and effective for patients who need to use it for many years[8][9].

Special Considerations

There are some important points to remember when taking tipranavir:

  • Drug interactions: Tipranavir can interact with many other medications. Always inform your healthcare provider about all drugs you’re taking.
  • Resistance: Tipranavir is often used in patients who have developed resistance to other HIV medications. Your doctor will perform tests to ensure tipranavir is still effective against your specific HIV strain.
  • Monitoring: Regular blood tests are necessary to check your viral load, CD4 count, liver function, and cholesterol levels.
  • Adherence: It’s crucial to take tipranavir exactly as prescribed to maintain its effectiveness and prevent the development of drug resistance.

Aspect Details
Main Focus Safety, efficacy, and pharmacokinetics of Tipranavir in HIV treatment
Patient Population HIV-infected patients, including those with limited treatment options or drug resistance
Common Combination Tipranavir with low-dose Ritonavir
Key Outcome Measures Viral load, CD4 cell count, adverse events, pharmacokinetic parameters
Safety Monitoring Adverse events, laboratory parameters (liver function, lipids, blood counts)
Study Types Bioequivalence, pharmacokinetics, long-term safety, efficacy, observational
Special Considerations Often used in treatment-experienced patients, requires regular monitoring

FAQ

  • What is Tipranavir and how is it used in HIV treatment? Tipranavir is an antiretroviral medication used to treat HIV infections. It is often used in combination with low-dose Ritonavir and other antiretroviral drugs, especially in patients who have developed resistance to other HIV medications or have limited treatment options.
  • What are some of the main focuses of Tipranavir clinical trials? Clinical trials for Tipranavir focus on various aspects, including its bioequivalence in different formulations, pharmacokinetics, long-term safety and tolerability, efficacy in suppressing viral load, and its use in patients with advanced HIV infection or limited treatment options.
  • How is the safety of Tipranavir evaluated in clinical trials? Safety is evaluated by monitoring adverse events, changes in laboratory parameters (such as liver function tests, cholesterol levels, and blood cell counts), and assessing the tolerability of the drug. Researchers also look at the number of patients who discontinue treatment due to side effects.
  • What are some of the outcome measures used in Tipranavir trials? Common outcome measures include changes in viral load (HIV-RNA levels), CD4 cell count, pharmacokinetic parameters like maximum drug concentration and area under the curve, and the incidence of adverse events. Some trials also assess patient-reported outcomes like quality of life.
  • Are there any special considerations for patients taking Tipranavir? Tipranavir is often used in combination with low-dose Ritonavir, which helps boost its effectiveness. It's typically prescribed for patients who have developed resistance to other HIV medications. Patients may need regular monitoring of liver function and lipid levels while on Tipranavir treatment.

Ongoing Clinical Trials on Tipranavir

  • Study on the Effects of Abacavir Sulfate and Etravirine in Pregnant Women with HIV

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Germany Ireland The Netherlands Spain

Glossary

  • Tipranavir: An antiretroviral medication used to treat HIV infections, often in combination with other drugs.
  • Ritonavir: An antiretroviral drug often used in low doses to boost the effectiveness of other HIV medications like Tipranavir.
  • Bioequivalence: The property of two drug formulations having the same biological effect and availability in the body.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Viral Load: The amount of HIV in a person's blood, usually measured as HIV-RNA copies per milliliter.
  • CD4 Cell Count: A measure of the number of CD4 T cells in the blood, which helps assess the strength of the immune system in HIV patients.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Protease Inhibitor: A class of antiretroviral drugs, including Tipranavir, that block the action of protease, an enzyme that HIV needs to replicate.
  • Antiretroviral Therapy (ART): The use of HIV medicines to treat HIV infection, usually involving a combination of different drugs.
  • Drug Resistance: The ability of HIV to mutate and reproduce itself in the presence of antiretroviral drugs, making the drugs less effective.

References

  1. https://clinicaltrials.gov/study/NCT00531206
  2. https://clinicaltrials.gov/study/NCT00146328
  3. https://clinicaltrials.gov/study/NCT00933205
  4. https://clinicaltrials.gov/study/NCT00062660
  5. https://clinicaltrials.gov/study/NCT02244190
  6. https://clinicaltrials.gov/study/NCT02253797
  7. https://clinicaltrials.gov/study/NCT00615290
  8. https://clinicaltrials.gov/study/NCT00805857
  9. https://clinicaltrials.gov/study/NCT00976950